Total Funding
50
39
Total FundingPost-IPO Equity raised
Growth Score 50 in past quarter
-2 pts
Heat Score 39 in past quarter
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
229224
RepliCel Life Sciences is a regenerative medicine company using cell therapy products for healing tendinosis, aging, and pattern baldness.
R. Lee Buckler: President & CEO, DirectorPast Role: Cell Therapy Group, Founder & Managing Director
Rolf Hoffmann: Chief Medical Officer
About the Company
RepliCel is a regenerative medicine company with a focus on aesthetics and orthopedics. Its cell therapy products are tailor-made to restore cellular function rejuvenate aging or sun-damaged skin, regrow hair, and repair tendons. The company's dermal injection technology is designed to revolutionize aesthetic treatment outcomes.
